Eagle Pharmaceuticals to Present BYFAVO (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference

-- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam

WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been selected to present a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care (“SNACC”) Annual Meeting being held September 8-10, 2023, in Alexandria, VA. The conference is designed to meet the educational needs of neurosurgical and critical care anesthesiologists and neuroscientists involved in the care of patients with neurological disorders.

“Byfavo is the first new sedative to come to market in over 20 years, and we are extremely grateful for the opportunity to present this analysis to our esteemed colleagues in the perioperative neuroscience community,” stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. “Gaining a better understanding of the potential impact of sedation agents on the central nervous system – as they relate to both short- and long-term changes in cognitive function – should help provide more precise patient care. We are excited to share these data, which suggest that changes in cognitive function, occurring after even a brief exposure, may be less pronounced with Byfavo compared with midazolam, when used in conjunction with fentanyl for procedural sedation.”

Details of the presentation are as follows:

Abstract	Comparing Relative Effects on Cognitive Function Following Sedation with Remimazolam vs Midazolam as Measured by the Hopkins Verbal Learning Test
Title:
Date:	Saturday, September 9, 2023
Time:	3:45pm ET
Location:	The Westin Alexandria Old Town (virtual participation option available)

About BYFAVO (remimazolam)¹ Injection:
Byfavo is a novel benzodiazepine approved by the U.S. Food and Drug Administration in July 2020 for sedation in patients undergoing procedures less than 30 minutes in duration. Esterase metabolism and biotransformation to an inactive metabolite provide unique pharmacokinetic differences compared with other benzodiazepines. In May, the Centers for Medicare & Medicaid Services (“CMS”) established a unique, product-specific billing code for Byfavo (remimazolam for injection), which became effective on July 1, 2023. For more information about Byfavo, visit byfavo.com.